These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

454 related items for PubMed ID: 21973023

  • 1. The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells.
    Rettinger E, Kuçi S, Naumann I, Becker P, Kreyenberg H, Anzaghe M, Willasch A, Koehl U, Bug G, Ruthardt M, Klingebiel T, Fulda S, Bader P.
    Cytotherapy; 2012 Jan; 14(1):91-103. PubMed ID: 21973023
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Implication of different effector mechanisms by cord blood-derived and peripheral blood-derived cytokine-induced killer cells to kill precursor B acute lymphoblastic leukemia cell lines.
    Durrieu L, Lemieux W, Dieng MM, Fontaine F, Duval M, Le Deist F, Haddad E.
    Cytotherapy; 2014 Jun; 16(6):845-56. PubMed ID: 24529554
    [Abstract] [Full Text] [Related]

  • 4. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
    Oelsner S, Wagner J, Friede ME, Pfirrmann V, Genßler S, Rettinger E, Buchholz CJ, Pfeifer H, Schubert R, Ottmann OG, Ullrich E, Bader P, Wels WS.
    Int J Cancer; 2016 Oct 15; 139(8):1799-809. PubMed ID: 27253354
    [Abstract] [Full Text] [Related]

  • 5. Cytomegalovirus-specific cytokine-induced killer cells: concurrent targeting of leukemia and cytomegalovirus.
    Pfirrmann V, Oelsner S, Rettinger E, Huenecke S, Bonig H, Merker M, Wels WS, Cinatl J, Schubert R, Klingebiel T, Bader P.
    Cytotherapy; 2015 Aug 15; 17(8):1139-51. PubMed ID: 26072027
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity.
    Pievani A, Borleri G, Pende D, Moretta L, Rambaldi A, Golay J, Introna M.
    Blood; 2011 Sep 22; 118(12):3301-10. PubMed ID: 21821703
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.
    Hoyle C, Bangs CD, Chang P, Kamel O, Mehta B, Negrin RS.
    Blood; 1998 Nov 01; 92(9):3318-27. PubMed ID: 9787169
    [Abstract] [Full Text] [Related]

  • 11. Interleukin-15 enhances cytokine induced killer (CIK) cytotoxic potential against epithelial cancer cell lines via an innate pathway.
    Iudicone P, Fioravanti D, Cicchetti E, Zizzari IG, Pandolfi A, Scocchera R, Fazzina R, Pierelli L.
    Hum Immunol; 2016 Dec 01; 77(12):1239-1247. PubMed ID: 27615504
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
    Zhang Q, Liu XY, Zhang T, Zhang XF, Zhao L, Long F, Liu ZK, Wang EH.
    Hum Immunol; 2015 May 01; 76(5):385-91. PubMed ID: 25305457
    [Abstract] [Full Text] [Related]

  • 14. Human interferon-alpha increases the cytotoxic effect of CD56(+) cord blood-derived cytokine-induced killer cells on human B-acute lymphoblastic leukemia cell lines.
    Durrieu L, Gregoire-Gauthier J, Dieng MM, Fontaine F, le Deist F, Haddad E.
    Cytotherapy; 2012 Nov 01; 14(10):1245-57. PubMed ID: 22974386
    [Abstract] [Full Text] [Related]

  • 15. Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts.
    Linn YC, Lau LC, Hui KM.
    Br J Haematol; 2002 Jan 01; 116(1):78-86. PubMed ID: 11841399
    [Abstract] [Full Text] [Related]

  • 16. Improving Clinical Manufacturing of IL-15 Activated Cytokine-Induced Killer (CIK) Cells.
    Bremm M, Pfeffermann LM, Cappel C, Katzki V, Erben S, Betz S, Quaiser A, Merker M, Bonig H, Schmidt M, Klingebiel T, Bader P, Huenecke S, Rettinger E.
    Front Immunol; 2019 Jan 01; 10():1218. PubMed ID: 31214182
    [Abstract] [Full Text] [Related]

  • 17. TRAIL-mediated killing of acute lymphoblastic leukemia by plasmacytoid dendritic cell-activated natural killer cells.
    Lelaidier M, Dìaz-Rodriguez Y, Cordeau M, Cordeiro P, Haddad E, Herblot S, Duval M.
    Oncotarget; 2015 Oct 06; 6(30):29440-55. PubMed ID: 26320191
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Phenotype and Function of Activated Natural Killer Cells From Patients With Prostate Cancer: Patient-Dependent Responses to Priming and IL-2 Activation.
    Hood SP, Foulds GA, Imrie H, Reeder S, McArdle SEB, Khan M, Pockley AG.
    Front Immunol; 2018 Oct 06; 9():3169. PubMed ID: 30761160
    [Abstract] [Full Text] [Related]

  • 20. Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation.
    Alvarnas JC, Linn YC, Hope EG, Negrin RS.
    Biol Blood Marrow Transplant; 2001 Oct 06; 7(4):216-22. PubMed ID: 11349808
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.